Compare HSDT & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HSDT | CNTB |
|---|---|---|
| Founded | N/A | 2012 |
| Country | United States | United States |
| Employees | 21 | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 77.6M | 128.6M |
| IPO Year | N/A | 2020 |
| Metric | HSDT | CNTB |
|---|---|---|
| Price | $2.16 | $2.67 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | ★ 344.6K | 107.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 75.22 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $26,033,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $75.13 | $24,617.69 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.26 | $0.51 |
| 52 Week High | $25.50 | $3.28 |
| Indicator | HSDT | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 48.04 | 52.08 |
| Support Level | $1.78 | $2.09 |
| Resistance Level | $2.37 | $2.86 |
| Average True Range (ATR) | 0.20 | 0.20 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 62.26 | 47.76 |
Solana Co is a publicly listed digital asset treasury established in partnership with Pantera and Summer Capital. The company is dedicated to acquiring Solana (SOL) and aims to maximize SOL per share by strategically leveraging capital market opportunities and on-chain activities. Through this model, Solana Company provides public market investors with efficient and direct exposure to Solana's long-term growth potential.
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.